Orthogon Therapeutics has closed an $11 million follow-on financing round, bringing their total raised to $36 million. This capital will fund the advancement of their first-in-class oral therapy targeting BK polyomavirus, a significant cause of complications in transplant patients with no current approved treatments. The company aims to address the full spectrum of BK infection with this novel approach.
